TWO-STEP PPD TESTING FOR NURSING HOME PATIENTS ON ADMISSION
*Last Updated February, 2003*

BACKGROUND

The American Geriatrics Society recommends, in order to establish baseline information, the practice of initial two-step PPD testing for all nursing home (NH) residents. Residents who react to either the first or second PPD skin test represent a reservoir of latent tuberculosis (TB) and are at risk to develop reactivation TB. Those residents who do not react to two-step PPD testing are immunologically naive to TB and susceptible to primary tuberculosis infection. Some may be anergic.

THE BOOSTER PHENOMENON

In persons who had initial infection and skin testing many years in the past, skin test reactivity may wane. Repeat skin testing on admission to a NH will then show little or no reaction. However, the small dose of PPD used in skin testing may stimulate an anamnestic immune response. This is known as boosting: A second skin test in the NH may be positive.4,12-14,21 The booster phenomenon can usually be demonstrated within a week of the initial skin test and will persist for at least a year. The booster phenomenon is more common in the elderly.13 There is no evidence that repeated PPD administration will by itself produce a positive skin test.

If a NH resident is negative after a single PPD skin test on admission and is then positive when next tested 6 or 12 months later, the conversion may be due either to the booster phenomenon or to the intercurrent development of primary infection. This potential ambiguity will be minimized by two-step PPD testing, in which a second PPD test is made one to three weeks after the first if the first test is negative. Those who are positive because of boosting will thus be identified. Then, those who convert with subsequent testing can be assumed to be newly infected.13-15 Because of cost implications, the periodicity of routine follow-up single-step PPD testing in NH residents who have had baseline two-step PPD testing must be defined by each institution considering local issues and prevalence. Retesting of the nursing home population is required when a TB exposure situation or potential outbreak of tuberculosis is identified. The Advisory Council for the Elimination of Tuberculosis recommends testing for the booster phenomenon when subsequent TB testing in the high risk population is likely, as it would be for the nursing home population. 28 The technical aspects of two-step PPD testing have been described in detail.12

EPIDEMIOLOGY

Following a period of resurgence of tuberculosis that began in the mid 1980's and peaked in 1992, the United States has reestablished control over the disease. From 1992 through 2000, the incidence of tuberculosis declined by 45%. In 2000, the TB incidence ratio was 5.8 cases/100,000 population, the lowest ever recorded in this country. 29

Tuberculosis, however, occurs with disproportionate frequency among the elderly.1,2 Elders living in communal settings such as nursing homes or other long-term care settings have a TB incidence rate approximately four times greater than the general population. 30 The aggregate tuberculosis incidence rate for nursing home residents is 1.8 times higher than the rate seen in elderly persons living in the community. 31 In several studies of patients entering NHs, the percentage of PPD reactors was 10% to 40%.2,4,5,32 Generally, the risk that a recent convertor will develop clinically active TB is highest in the first two years after conversion and then falls.3,6 However, in PPD reactors over the age of seventy years, the case rate of active TB among known reactors may increase greatly.7 The most prevalent risk factors in the nursing home for development of active tuberculosis were diabetes (42%) , being more than 10% below ideal body weight (41.5%), and alcohol abuse (13%). 32 After two-step testing, 60% to 90% of patients entering NHs are PPD negative and are, therefore, non-immune to new infection, although 5-10% of non-reactors to PPD may be anergic. These patients are at a risk of infection if exposed and of progression to clinically active TB if not then treated. Nonreactors are vulnerable even though many of them may have been PPD positive previously.2,7,8 Anergy, which may occur with active TB infection or other forms of immune suppression, accounts for very few nonreactors.9

CHOOSING A THRESHOLD

Although PPD testing is imperfect, it has been shown to have considerable validity, even in thin-skinned older people.5 Variability in PPD solution, its administration and the measurement of reaction is significant.16 Therefore, caution is needed in the interpretation of small changes in the size of a reaction. Many clinicians recommend the "ball-point pen" measurement technique of Sokal (movement of a pen toward the site of a PPD injection from two opposite sides and measurement of the distance between the points where the pen was stopped by induration).20 Cross-reactivity with nontuberculous mycobacterium (NTM) is problematic.17 Therefore, history of contact, clinical picture and regional prevalence of TB and NTM should all affect the clinician's choice of a PPD threshold for reactivity.4,18,24-27 The Center for Disease Control has published guidelines for threshold definition, screening in high risk populations and recommendations for prevention.24-27 The decision to treat should consider, in addition to the skin test, clinical picture, and chest x-ray findings, an ethical balance of the individual resident's best interests and the interests of the community.

CONCLUSION

NHs bring a relatively large population of patients infected with TB into close contact with an even larger population who are highly susceptible to infection. Several reports demonstrate endemic and epidemic new TB infection among NH residents.2,4,5,9 The diagnosis of TB may be difficult.10,11 Initial two-step PPD testing will more accurately identify residents who are immunologically naive to TB. If these patients subsequently become skin-test positive, they are at increased risk of developing clinically active disease. Defining a threshold for PPD positivity and deciding whether to treat are complex issues that require institutional and patient-specific judgment. Many states require, unless specifically contraindicated, that all nursing home residents receive 2 step PPD testing upon admission, and, if negative, surveillance would be done with a single step test periodically thereafter. The American Geriatrics Society recommends that all states adopt such regulations.

ACKNOWLEDGEMENTS

The author would like to acknowledge the generous and expert assistance of Drs. William W. Stead and Gene H. Stollerman position statement.

REFERENCES

  1. Reichman, LB, O'Day R: Tuberculosis infection in a large urban population. Am Rev Resp Des 117:705-712, 1978.

  2. Narain J, Lofgren J, Warren E, et al: Epidemic tuberculosis in a nursing home: A retrospective cohort study. J Am Geriatr Soc 33:258-263, 1985.

  3. Powell, KE, Farer, LS: The rising age of the tuberculosis patient: A sign of success and failure. J Infect Dis 142:946-948, 1980.

  4. Welty C, Burstin S, Muspratt S, et al: Epidemiology of tuberculous infection in a chronic care population. Am Rev Resp Dis 132:133-136, 1985.

  5. Stead W, Lofgren J, Warren E, et al: Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 312:1483-1487, 1985.

  6. Comstock GW: Frost revisited: The modern epidemiology of tuberculosis. An J Epidem 101:363-282, 1975.

  7. Stead W, Lofgren JP: Does the risk of tuberculosis increase in old age? J Infect Dis 147:951-955, 1983.

  8. Davidson PT: Tuberculosis: New views of an old disease. N Engl J Med 321:1514-1515, 1985.

  9. Stead W: Tuberculosis among elderly persons: An outbreak in a nursing home. Ann Int Med 94:606-610, 1981.

  10. Rudd A: Tuberculosis in a geriatric unit. J Am Ger Soc 33:566-569, 1985.

  11. Bobrowitz I: Active tuberculosis undiagnosed until autopsy. Am J Med 72: 650-658, 1982.

  12. Comstock GW, Woolpert SF: Tuberculin conversions: True or false? AmRev Resp Dis 118:215-217, 1978.

  13. Thompson NJ, Glassroth JL, Snider DE, et al: The booster phenomenon in serial tuberculin testing. Am Rev Resp dis 119:587-597, 1979.

  14. Bass JB, Serio, RA: The use of repeat skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Resp Dis 123:394-396, 1981.

  15. Ad Hoc Committee of the Scientific Assembly on TB: The tuberculin skin test.Am Rev Resp Dis 124:356-363, 1981.

  16. Chaparas SD, Vandiviere HM, Melvin I, et al: Tuberculin test. Am Rev Resp Dis 132:175-177, 1985.

  17. Edwards LB, Aquaviva FA, Legersay VT: Identification of tuberculous infection. Am Rev Resp Dis 109:1334, 1973.

  18. Bass JB, Sanders RV, Kirkpatrick MB: Choosing an appropriate cutting point for conversion in annual tuberculin skin testing. Am Rev Resp Dis 132:279-381, 1985.

  19. Control of tuberculosis. Am Rev Resp Dise 127:336-342, 1983.

  20. Sokal JE: Measurement of delayed skin test response. N Engl J Med 293:501-502, 1975.

  21. Barry MA, Regan AM, Kunches, LM, et al: Two-stage tuberculin testing with control antigens in patients residing in two chronic disease hospitals. J Am Geriatr Soc 35:147-153, 1987.

  22. Comstock GW: Prevention of tuberculosis among tuberculin reactors: Maximizing benefits, minimizing risks. JAMA 256:2729-2730, 1986.

  23. Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis: A decision analysis for low-risk tuberculin reactors. JAMA 256:2709-2713, 1986.

  24. Centers for Disease Control. Prevention and control of tuberculosis in facilities providing long-term care to the elderly: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR. 1990; (RR-8):7-20.

  25. Centers for Disease Control. Screening for tuberculosis and tuberculous infection in high-risk populations: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR. 1990;39 (RR-8):1-7.

  26. Centers for Disease Control. The use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR. 1990;39(RR-8):9-12.

  27. Lefrak, S: Tuberculosis Screening in a Nursing Home: Indications for Preventive Therapy. JAMA 266(14):2000-2003, 1991.

  28. Centers for Disease Control. Screening for Tuberculosis and Tuberculosis Infection in High Risk Populations: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR. 1995; 44:018.

  29. Centers for Disease Control. Progress Toward Tuberculosis Elimination in Low-Incidence Areas of the United States: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR. 2002;51:1-16.

  30. Schultz M, Hernandez JM, Hernandez NE, Sanchez RO. Onset to tuberculosis disease: new converters in long-tgerm care settings. Am J Alzheimers Dis and other demen 2001; 16:313-318.

  31. Hutton MD, Cauthen GM, Bloch AB. Results of a 29-state survey of tuberculosis in nursing homes and correctional facilities. Public Health Rep 1993;108:305-14.

  32. Vega Torres RA, Conde JG, Diaz M. Prevalence of tuberculin reactivity and risk factors for the development of active tuberculosis upon admission to a nursing home. P R Health Sci J 1996;15:275-7.

Developed by the Clinical Practice Committee and approved by the American Geriatrics Society Board of Directors. Revised November 1991. Reviewed and updated 1993. Reviewed in 1997. The American Geriatrics Society, The Empire State Building, 350 Fifth Avenue, Suite 801, New York, NY 10118, 212-308-1414, Fax: 212-832-8646, info.amger@americangeriatrics.org.